Healthcare provider profile · identity verified

Ryan J Kula, MD

Family Practice · LONGMONT, CO · NPI 1144783085

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	266	91
Levothyroxine Sodium	Levothyroxine Sodium	185	58
Lisinopril	Lisinopril	173	54
Amlodipine Besylate	Amlodipine Besylate	163	59
Rosuvastatin Calcium	Rosuvastatin Calcium	118	38
Omeprazole	Omeprazole	113	37
Metformin Hcl	Metformin Hcl	91	28
Gabapentin	Gabapentin	89	34
Simvastatin	Simvastatin	89	29
Losartan Potassium	Losartan Potassium	83	32
Tamsulosin Hcl	Tamsulosin Hcl	81	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	21
Pantoprazole Sodium	Pantoprazole Sodium	54	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	52	48
Hydrochlorothiazide	Hydrochlorothiazide	52	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	13
Metformin Hcl Er	Metformin Hcl	41	15
Eliquis	Apixaban	39	14
Fluoxetine Hcl	Fluoxetine Hcl	36	14
Clonazepam	Clonazepam	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	13
Sertraline Hcl	Sertraline Hcl	33	11
Allopurinol	Allopurinol	32	11
Metoprolol Succinate	Metoprolol Succinate	32	12
Tramadol Hcl	Tramadol Hcl	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	20
Finasteride	Finasteride	29	14
Trazodone Hcl	Trazodone Hcl	29	12
Furosemide	Furosemide	26	11
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Celecoxib	Celecoxib	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	11
Lorazepam	Lorazepam	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Ozempic	Semaglutide	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Atenolol	Atenolol	18	suppressed
Azithromycin	Azithromycin	18	17
Famotidine	Famotidine	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	13
Testosterone	Testosterone	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	17	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Diazepam	Diazepam	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Alendronate Sodium	Alendronate Sodium	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Prednisone	Prednisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error